Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 17/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | MC5R | P33032 | 5/20 | 0.38 |
| ▸ | MC3R | P41968 | 4/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | MC1R | Q01726 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1945992 | 0.88 | KDM4E (0.43) | MC4R | |
| SCHEMBL1946770 | 0.81 | DPP4 (0.47) | MC4RMC5RMC3RKCNH2DPP4 | |
| SCHEMBL3262709 | 0.80 | MC4R (0.52) | MC4RMC5RMC3RKCNH2SLC6A9 | |
| SCHEMBL13493164 | 0.80 | MC4R (0.52) | MC4RMC5RMC3RKCNH2SLC6A9 | |
| SCHEMBL2307986 | 0.80 | PANK3 (0.42) | MC4RMC5RMC3RKCNH2 | |
| SCHEMBL2307114 | 0.78 | BRD4 (0.42) | — | |
| SCHEMBL1920759 | 0.77 | MC4R (0.45) | MC4RMC5RMC3RKCNH2MC1R | |
| SCHEMBL1945899 | 0.74 | PDE10A (0.34) | NTRK1 | |
| SCHEMBL1919957 | 0.73 | MC4R (0.49) | MC4RMC5RMC3RKCNH2MC1R | |
| SCHEMBL1920256 | 0.72 | MC4R (0.48) | MC4RMC5RMC3RKCNH2MC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136814-A1 | Diazepine and Diazocane Compounds As MC4 Agonists | ANDREWS MARK DAVID | 2011-06-09 | — | — | US | disclosed |
| EP-2326638-A1 | DIAZEPINE AND DIAZOCANE COMPOUNDS AS MC4 AGONISTS | Pfizer Limited (GB) | 2011-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136814-A1 | Diazepine and Diazocane Compounds As MC4 Agonists | MC4R, CHRM4, GPR4 | MC4R 1/4885NTRK1 766/4885MC5R 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.